On Sept. 18, 2020, Sanofi and GSK finalised and signed an advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved.

The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

This final agreement confirmed the announcement made on July 31 by both companies and marks a key milestone in protecting European populations against COVID-19.